Evidence map›Paper›PMID 21182082›Full record

ArticleEuropean journal of immunology2011

CD4+ T-cell immunity to the Burkholderia pseudomallei ABC transporter LolC in melioidosis.

Karen K Chu, Patcharaporn Tippayawat, Nicola J Walker, Sarah V Harding, Helen S Atkins, Bernard Maillere, Gregory J Bancroft, Ganjana Lertmemongkolchai, Daniel M Altmann

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. LVS ΔmBio · 2024
    Article
  2. Vaccines · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Karen K ChuHuman Disease Immunogenetics Group, Department of Infectious Diseases and Immunity, Imperial College, London, UK.
Patcharaporn Tippayawat
Nicola J Walker
Sarah V Harding
Helen S Atkins
Bernard Maillere
Gregory J Bancroft
Ganjana Lertmemongkolchai
Daniel M Altmann
Defence Science and Technology Laboratory · GBImperial College London · GBKhon Kaen University · THCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRLondon School of Hygiene & Tropical Medicine · GB

Funding

Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
Scanning B. pseudomallei proteome for vaccine antigensU01AI061363 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2004 to 2008
$5.7M
NIAID NIH HHS U01 AI061363NIAID NIH HHS U54 AI065359PHS HHS HHSN266200400084C
6 · The paper itself

Abstract

Burkholderia pseudomallei causes melioidosis, a disease with a wide range of possible outcomes, from seroconversion and dormancy to sepsis and death. This spectrum of host-pathogen interactions poses challenging questions about the heterogeneity in immunity to B. pseudomallei. Models show protection to be dependent on CD4(+) cells and IFN-γ, but little is known about specific target antigens. Having previously implicated the ABC transporter, LolC, in protective immunity, we here use epitope prediction, HLA-binding studies, HLA-transgenic models and studies of T cells from seropositive individuals to characterize HLA-restricted LolC responses. Immunized mice showed long-lasting memory to the protein, whereas predictive algorithms identified epitopes within LolC that subsequently demonstrated strong HLA class II binding. Immunization of HLA-DR transgenics with LolC stimulated T-cell responses to four of these epitopes. Furthermore, the responsiveness of HLA transgenics to LolC revealed a hierarchy supportive of HLA polymorphism-determined differential susceptibility. Seropositive human donors of diverse HLA class II types showed T-cell responses to LolC epitopes, which are conserved among Burkholderia species including Burkholderia cenocepacia, associated with life-threatening cepacia complex in cystic fibrosis patients and Burkholderia mallei, which causes glanders. These findings suggest a role for LolC epitopes in multiepitope vaccine design for melioidosis and related diseases.

Indexed as

AnimalsATP-Binding Cassette TransportersBurkholderia cenocepaciaBurkholderia malleiBurkholderia pseudomalleiCD4-Positive T-LymphocytesFemaleGlandersHistocompatibility AntigensHLA AntigensHumansMaleMelioidosisMiceMice, Inbred BALB CMice, TransgenicATP-Binding Cassette TransportersHistocompatibility AntigensHLA Antigens

Identifiers

PMID21182082
PMCPMC3147111
OpenAlexW1978716067

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.